Targeting HER 1 and 2 in breast cancer with lapatinib
AbstractNumerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, development of resistance to trastuzumab left patients with no therapeutic option other than specifically targeted HER2. This paper provides an in-depth review of lapatinib, a dual HER kinase inhibitor, as well as some insight into three HER family members, in breast cancer.
- Abstract views: 903
- FULL TEXT: 140
Copyright (c) 2011 Gerald M. Higa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.